Company Shares of Hologic (NASDAQ:HOLX) Rally 3.1%

Hologic (NASDAQ:HOLX) : Traders are bullish on Hologic (NASDAQ:HOLX) as it has outperformed the S&P 500 by a wide margin of 3.57% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 1.79%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 3.1% in the last 1 week, and is up 5.24% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The company shares have dropped -8.44% from its 1 Year high price. On Aug 18, 2015, the shares registered one year high at $43.00 and the one year low was seen on Feb 12, 2016. The 50-Day Moving Average price is $34.16 and the 200 Day Moving Average price is recorded at $34.98.

The stock has recorded a 20-day Moving Average of 5.29% and the 50-Day Moving Average is 5.38%.


Hologic (NASDAQ:HOLX): stock turned positive on Friday. Though the stock opened at $35.63, the bulls momentum made the stock top out at $36.03 level for the day. The stock recorded a low of $35.52 and closed the trading day at $35.93, in the green by 1.21%. The total traded volume for the day was 1,887,656. The stock had closed at $35.5 in the previous days trading.

In an insider trading activity, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director of Hologic Inc, Levy Lawrence M had sold 17,794 shares worth of $612,292 in a transaction dated June 1, 2016. In this transaction, 17,794 shares were sold at $34.41 per share.

Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products. The Companys business units are focused on diagnostics, breast health, GYN surgical and skeletal health. The Companys diagnostics products include Aptima family of assays, its ThinPrep system, the Rapid Fetal Fibronectin Test and its Procleix blood screening assays. The Aptima family of assays is used to detect the infectious microorganisms that cause the common sexually transmitted diseases, chlamydia and gonorrhea, certain high-risk strains of human papillomavirus (HPV), and Trichomonas vaginalis, the parasite that causes trichomoniasis. The Companys GYN surgical products include its NovaSure Endometrial Ablation System and its MyoSure Hysteroscopic Tissue Removal System. The skeletal health products include dual-energy X-ray bone densitometry systems, an ultrasound-based osteoporosis assessment product, and its Fluoroscan mini C-arm imaging products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.